INTRODUCTION
============

The endoplasmic reticulum (ER) is a central hub for protein and lipid metabolism, and disruptions in ER homeostasis can trigger the unfolded protein response (UPR). The UPR features translational and transcriptional control mechanisms that collectively serve to enhance protein folding and assembly, thereby expanding the capacity of the ER to process proteins slated for the secretory pathway ([@B65]; [@B2]; [@B1]). In addition, the ER is instrumental for intermediary and complex lipid metabolism ([@B21]). Among lipids, prudent regulation of cholesterol synthesis is critical, as cholesterol helps to order phospholipids in membranes. UPR sensory proteins, such as the type 1 ER transmembrane protein kinase PERK (EIF2AK3/PEK), are activated by disruptions in protein folding or membrane compositions. The ensuing PERK phosphorylation of the α subunit of eIF2 (eIF2α-P) represses global protein synthesis, thereby reducing influx of nascent polypeptides into the overloaded ER. Coincident with global translational control, eIF2α-P enhances preferential translation of a subset of stress-related mRNAs, including *ATF4* (*CREB2*), a transcriptional activator of UPR target genes ([@B25]; [@B64]; [@B16]). Because eIF2α-P induces *ATF4* translational expression in response to a range of environmental and physiological stresses in addition to those afflicting the ER, the ATF4-directed regulatory scheme has been referred to as the integrated stress response ([@B25]; [@B2]).

ATF4 serves to enhance transcriptional expression of genes involved in amino acid metabolism and resistance to oxidative stress ([@B3]; [@B25]; [@B49]; [@B30]). Furthermore, ATF4 functions to induce transcription of another transcription factor, CHOP (GADD153/DDIT3), and ATF4 and CHOP independently or in combination are believed to coordinate key facets of the UPR transcriptional and translational control directed by PERK ([@B66]; [@B38]; [@B25]; [@B40]; [@B54]; [@B23]; [@B56]). For example, together ATF4 and CHOP induce the expression of *GADD34*, which serves to direct feedback dephosphorylation of eIF2α-P ([@B13]; [@B44]; [@B7]; [@B40]; [@B24]). ATF4 and CHOP also function in a feedforward loop to induce expression of a related transcription factor ATF5, and this transcription network is central for determining cell fate in response to ER stress ([@B56]). It is important to emphasize that the ATF4-directed transcriptome has been defined largely by analyses of cultured cells, especially mouse embryo fibroblast (MEF) cells, and an important question is whether ATF4 is the primary effector of gene expression evoked by eIF2α-P during ER stress in vivo.

In addition to PERK, two other UPR sensors, ATF6 and IRE1, function to regulate transcriptional expression. Upon ER stress, ATF6 is trafficked from the ER to the Golgi, where it is proteolytically cleaved, releasing the N-terminal ATF6 segment, a transcription factor of genes involved in the folding and trafficking of proteins slated for the secretory pathway ([@B26]; [@B74]; [@B12]; [@B52]; [@B70]; [@B71]). IRE1 facilitates cytosolic splicing of *XBP1* mRNA, allowing translation of active XBP1s, which enhances transcriptional expression of genes that participate in protein folding, degradation of unfolded or misfolded proteins, and membrane expansion and renewal ([@B53]; [@B58]; [@B75]; [@B9]; [@B33], [@B32]; [@B73]; [@B27]).

The UPR sensors PERK, ATF6, and IRE1 pathways are often viewed as functioning in parallel, and each branch of the UPR is suggested to have the potential for different effects on cell viability ([@B51]; [@B71]; [@B65]). For example, PERK is posited to promote cell death by enhancing *CHOP* expression, whereas IRE1 is suggested to promote cell survival during ER stress ([@B34], [@B35]; [@B71]). The premise of distinct sensory pathways in the UPR is challenged by emerging findings that there is cross-regulation between the UPR branches. This is illustrated by the report that loss of *PERK* in cultured cells or livers of mice or deletion of *ATF4* in cultured MEF cells substantially ablated activation of ATF6 and reduced expression of XBP1s during ER stress ([@B57]). This cross-talk in the UPR can also regulate PERK, with, for example, XBP1s inducing transcriptional expression of p58^IPK^, which is reported to lower PERK phosphorylation of eIF2α and translational control ([@B32]; [@B59]). Therefore it is likely that the UPR represents an interconnected network of regulatory proteins that function together to modulate gene expression and help to restore protein homeostasis during the progression of the UPR ([@B5]).

In this study, we evaluated the central role of ATF4 in controlling transcriptional expression directed by PERK. To determine the functional roles of ATF4 in the UPR, we measured the UPR transcriptome in mice deleted for *ATF4* in the liver and compared those changes with gene expression patterns altered by depletion of *ATF4* in cultured cells. Using molecular, cellular, and biochemical assays, we found that basal expression of *ATF4* lowered oxidative stress, and *ATF4* contributed to cholesterol homeostasis in the liver independent of stress. Of importance, we showed that ATF4 was required for only a subset of PERK-dependent genes in vivo. Distinct from loss of *PERK* in the liver, we found that deletion of *ATF4* in the liver was not required for induction of either UPR transcription factor CHOP or ATF6 during ER stress. Furthermore, deletion of ATF4 showed a 10-fold increase in hepatocyte cell death in response to ER stress. Although significant, the level of cell death resulting from deletion of ATF4 in the liver was only a fraction of the cell death determined for *PERK* deficiency.

RESULTS
=======

UPR signaling varies upon ATF4 loss in different cell types
-----------------------------------------------------------

UPR studies featuring MEF cells subjected to pharmacological induction of ER stress indicated that ATF4 directs transcriptional expression of genes involved in amino acid metabolism, oxidative stress reduction, and control of apoptosis ([@B25]). To address the role of ATF4 in the UPR in hepatocytes, we depleted *ATF4* expression in the mouse hepatoma cell line Hepa1-6 using short hairpin RNA (shRNA) and compared the induction of key UPR genes with that of MEF cells deleted for ATF4 ([Figure 1, A--D](#F1){ref-type="fig"}). There was a significant reduction in *ATF4* mRNA and protein in the shATF4 cells compared with control after 3 or 6 h of treatment with 2 μM tunicamycin, an inhibitor of N-glycosylation of proteins in the ER and potent inducer of ER stress ([Figure 1, C and D](#F1){ref-type="fig"}). Known ATF4-target genes involved in amino acid metabolism, including *ASNS*, encoding asparagine synthetase, which catalyzes the conversion of aspartate to asparagine, and *FGF21*, which serves in the metabolic adaptation to fasting, were also reduced ([@B3]; [@B11]; [@B15]; [@B69]). ATF4, through heterodimerization with C/EBPγ, can also provide for resistance to oxidative stress by enhancing the expression of several genes in the glutathione pathway, including *CTH*, encoding cystathionine γ-lyase ([@B18]; [@B28]). Loss of C/EBPγ or ATF4 has been shown to reduce levels of glutathione (GSH) in MEF cells ([@B18]; [@B28]). There were increased levels of *ASNS*, *FGF21*, and *CTH* mRNAs in both the Hepa1-6 and MEF cells treated with tunicamycin, and this induction was significantly ablated upon loss of *ATF4* ([Figure 1, A and C](#F1){ref-type="fig"}). Emphasizing the importance of cross-regulation in the UPR, ATF4 was also required for full induction of *XBP1t* mRNA and its spliced variant *XBP1s* during ER stress ([Figure 1, A and C](#F1){ref-type="fig"}).

![Hepa1-6 cells demonstrate ATF4-independent CHOP expression. (A) WT and *ATF4*^−*/*−^ MEF cells were treated with 2 μM tunicamycin (Tm) for 6 h or given no stress treatment (NT), and levels of *ATF4*, *CHOP*, *FGF21*, *ASNS*, *CTH*, *SOD2*, *XBP1t*, and *XPB1s* mRNAs were determined by qPCR. (B) WT and *ATF4*^−*/*−^ MEF cells were treated with 2 μM tunicamycin for 3 or 6 h, and ATF4 and CHOP levels were evaluated by immunoblot analyses using specific antibodies. Levels of mRNAs (C) and proteins (D) were measured in in Hepa1-6 shCtrl and Hepa1-6 shATF4 cells by qPCR and immunoblot analyses, respectively. (E) MDA analysis on Hepa1-6 shCtrl and shATF4 cells was performed using BioVision Lipid Peroxidation Kit. (F) Hepa1-6 and Hepa1-6 shATF4 cells were plated on glass-bottom plates and then evaluated using MitoTracker Red. Top, images of the red fluorescent dye that stains mitochondria in live cells; bottom, quantitation indicated by histograms. \**p* \< 0.05 indicates statistical significance with respect to the treated samples between the two cell types, ^\#^*p* \< 0.05 indicates statistical significance with respect to the untreated samples between the two cell types, and ^\$^*p* \< 0.05 indicates statistical significance between untreated sample vs. ER stress for each cell type.](1536fig1){#F1}

Our comparison between ATF4-directed gene expression in Hepa1-6 and MEF cells also showed key differences between the two cell types. ATF4 is required for full cleavage to the active N-terminal version ATF6(N) in MEF cells treated with tunicamycin ([@B57]). As previously shown, the loss of ATF4 in the MEF cells led to a reduction in full-length ATF6 protein by 67% at 6 h, with a more pronounced 97% reduction of ATF6(N). However, the role of ATF4 in the activation of ATF6(N) was largely diminished in Hepa1-6 cells ([Figure 1, B and D](#F1){ref-type="fig"}). In the case of *SOD2*, encoding superoxide dismutase 2, which serves to clear reactive oxygen species (ROS) from mitochondria, deletion of *ATF4* in MEF cells led to higher levels of *SOD2* mRNA in both basal and ER stress conditions, whereas loss of *ATF4* expression in Hepa1-6 cells led to a substantial reduction of *SOD2* transcripts in both stressed and nonstressed conditions.

Given the reported antioxidation role of ATF4 in MEF cells ([@B25]), we also addressed whether there was generation of oxidative stress in the Hepa1-6 cells upon loss of ATF4. We assessed the oxidation status in shATF4 and control cells by measuring malondialdehyde (MDA), which is generated by lipid peroxidation. Depletion of *ATF4* in Hepa1-6 cells grown DMEM, which features high levels of glucose, did not affect the accumulation of MDA ([Figure 1E](#F1){ref-type="fig"}). Furthermore, we measured mitochondrial function by using the MitoTracker Red assay to measure mitochondrial membrane potential. There was a greater-than-twofold reduction in the mitochondrial potential upon depletion of *ATF4*, which was similar to the lowered levels by treatment with rotenone (Rot), a potent inhibitor of mitochondrial respiration ([Figure 1F](#F1){ref-type="fig"}).

CHOP is considered to be a canonical downstream effector of the PERK/ATF4 pathway, and, as expected, we observed a sharp increase in *CHOP* mRNA and protein levels in MEF cells treated with tunicamycin, which was significantly reduced upon deletion of *ATF4* ([Figure 1, A and B](#F1){ref-type="fig"}). However, in Hepa1-6 cells, the substantial increase in *CHOP* transcripts observed during ER stress was only modestly reduced upon depletion of ATF4, and there was full induction of CHOP protein even with depleted *ATF4* expression ([Figure 1, C and D](#F1){ref-type="fig"}). These results suggest that many features of UPR gene expression networks described in MEF cells cannot be applied to every cell type and that UPR regulators other than ATF4 can contribute to *CHOP* expression.

Loss of ATF6 in Hepa1-6 cells reduces *CHOP* expression
-------------------------------------------------------

A previous study of CHO and COS-1 cell lines suggested that ATF6 can contribute to *CHOP* expression by an ER-stress element situated in the *CHOP* promoter ([@B38]). We addressed the role played by ATF6 in *CHOP* expression in Hepa1-6 cells by depleting ATF6 using shRNA, followed by treatment with 2 μM tunicamycin. Loss of ATF6 led to reductions in the expression of well-defined ATF6-target genes, including ER chaperone *BiP* (*GRP78*/*HSPA5*) and *XBP1*t and its spliced variant *XBP1s* ([Figure 2A](#F2){ref-type="fig"}; [@B75]; [@B4]). *ATF4* mRNA levels were also modestly reduced in the *ATF6*-depleted cells treated with tunicamycin, but there was no measurable reduction in ATF4 protein levels ([Figure 2, A and B](#F2){ref-type="fig"}). Of importance, depletion of *ATF6* sharply lowered the induction of *CHOP* mRNA and protein upon ER stress in the Hepa1-6 cells. The CHOP protein levels were reduced by 76 and 51% at 3 and 6 h, respectively. These results suggest that ATF6 can be a major contributor to *CHOP* expression, especially during ER stress. To address whether other ATF transcription factors regulated by PERK can effect *CHOP* expression, we depleted *ATF5* expression in Hepa1-6 cells using shRNA and found no changes in induced expression of CHOP protein by ER stress ([Figure 2C](#F2){ref-type="fig"}). These findings indicate that the requirement of ATF6 for induced *CHOP* expression in the Hepa1-6 hepatocytes is not broadly shared among other transcription factors controlled by PERK.

![ATF6 facilitates induced *CHOP* expression in liver cells subjected to ER stress. (A) Hepa1-6 shCtrl and Hepa1-6 shATF6 cells were treated with 2 μM Tm for 6 h or given no stress treatment (NT), and the levels of *ATF4*, *CHOP*, *ATF6*, *XBP1t*, *XBP1s*, and *BiP* mRNAs were determined by qPCR. (B) Hepa1-6 shCtrl and Hepa1-6 shATF6 cells were treated with 2 μM Tm for 3 or 6 h, and ATF4, ATF6, and CHOP levels were evaluated by immunoblot analyses. CHOP levels were quantified using ImageJ based on three independent experiments for the 3- and 6-h time points. (C) Hepa1-6 shCtrl and Hepa1-6 shATF5 cells were treated with 2μM Tm for 3 or 6 h, and levels of ATF5 and CHOP proteins were measured by immunoblot analyses. (D) Hepa1-6 shCtrl, shATF4, shATF6, and shCHOP cells were treated with 2 μM Tm or 1 μM MG132 for 24 h or given no stress treatment. Cell proliferation was analyzed via Hoechst fluorescence, and cell death was measured by calcein fluorescence. \**p* \< 0.05 indicates statistical significance with respect to the treated samples between the indicated cell types, and ^\#^*p* \< 0.05 indicates statistical significance with respect to the untreated samples between the cell types.](1536fig2){#F2}

CHOP can direct the expression of genes involved in protein homeostasis, in particular those promoting protein folding, such as *HSPA1B* and *DNAJ4*, and a number of aminoacyl tRNA-synthetases, including WARS ([@B40]; [@B39]; [@B23]; [@B56]). By contrast, during prolonged ER stress triggered by pharmacological agents, CHOP can instead trigger cell death through expression of proapoptotic genes such as *BIM* or *GADD34* ([@B40]; [@B39]; [@B47]; [@B45]; [@B56])

We wished to determine whether depletion of the upstream regulator ATF6 or ATF4 altered Hepa1-6 survival upon treatment with either tunicamycin or another stress agent, the proteasome inhibitor MG132. As expected, Hepa1-6 cells depletion of *CHOP* showed protective effects upon either stress treatment as judged by lowered calcein-AM labeling ([Figure 2D](#F2){ref-type="fig"}). Lowered expression of either *ATF4* or *ATF6* led to significant increases in cell death upon ER stress of 20 and 15%, respectively, compared with control cells. These findings are consistent with the protective effects attributed to the ATF4 and ATF6 transcription factors in the UPR ([@B25]; [@B71]).

ATF4 and ATF6 contribute to induced *CHOP* expression during nutrient stress
----------------------------------------------------------------------------

We next addressed whether ATF4 and ATF6 contribute to *CHOP* expression in response to a stress that does not directly perturb the ER. Halofuginone has been shown to deplete the charging of tRNA^Pro^, leading to activation of GCN2, another eIF2 kinase, which can in turn enhance the transcriptional and translational expression of *ATF4* and *CHOP* ([@B55]; [@B46]). Treatment of Hepa1-6 cells with 50 nM halofuginone for 6 h led to significant increases in *ATF4* and *CHOP* mRNAs and proteins ([Figure 3, A--C](#F3){ref-type="fig"}). Loss of either ATF6 or ATF4 substantially lowered both *CHOP* mRNA and protein ([Figure 3, A--C](#F3){ref-type="fig"}). Expression of *GADD34* mRNA and protein was largely dependent on ATF4, with further increases in *GADD34* induction upon depletion of *ATF6*. Despite there being robust eIF2α-P and induction of *ATF4*, *CHOP*, and *GADD34* mRNAs in response to halofuginone, the increase in ATF4, CHOP, and GADD34 proteins was reproducibly less than with tunicamycin treatment ([Figure 1C](#F1){ref-type="fig"}). This difference in the levels of induced CHOP and ATF4 proteins may be a consequence of the diminished Pro-tRNA^Pro^ available for protein synthesis during halofuginone treatment.

![ATF6 contributes to CHOP expression in multiple stresses. Hepa1-6 cells expressing shCtrl, shATF6, or shATF4 were treated with 2 μM Tm or 50 nM halofuginone (HF) for 6 h or given no stress treatment (NT), as indicated. (A, B) Levels of the indicated gene transcripts were measured by qPCR. (C) The amounts of the indicated proteins were measured by immunoblot analyses. (D) Hepa1-6 cells were cotransfected with 5x ATF6 Binding Element Luciferase construct and *Renilla*. After 24 h, cells were treated with 2 μM Tm or 50 nM HF, and prepared, and firefly luciferase normalized for *Renilla* was measured for prepared lysates. (E) Model of the roles of ATF4 and ATF6 on expression of *CHOP* during ER stress and cytosolic stress triggered by HF treatment. \**p* \< 0.05 indicates statistical significance between ER stress--treated cells, ^\#^*p* \< 0.05 indicates significance for untreated cells, and ^\$^*p* \< 0.05 indicates significance for untreated cells.](1536fig3){#F3}

Consistent with the idea that the treatment regimen of halofuginone did not elicit ER stress, there was no increase in the levels of *XBP1*t mRNA, and the amount of *XBP1*s transcript was in fact substantially lower in Hepa1-6 cells exposed to halofuginone. ATF6 was suggested to contribute to *CHOP* expression, and there was a threefold increase in *ATF6* mRNA levels during halofuginone treatment. Although we did not measure appreciable activated ATF6(N) protein upon halofuginone treatment by immunoblot analyses, there was a twofold increase in ATF6-directed transcription as measured by a luciferase reporter assay, which was significant although reduced compared with the ∼15-fold enhancement during tunicamycin treatment ([Figure 3D](#F3){ref-type="fig"}). These results suggest a model in which nutrient stress afflicting the cytosol induces both ATF4 and ATF6 to contribute to increased *CHOP* expression. By comparison, ER stress triggers a pathway that is largely dependent upon ATF6 for *CHOP* expression ([Figure 3E](#F3){ref-type="fig"}).

ATF4 is dispensable for induced expression of *CHOP* in the liver during ER stress
----------------------------------------------------------------------------------

The identification of ATF4-independent induction of *CHOP* expression in Hepa1-6 cells subjected to ER stress raises the question of whether this pattern of gene expression also occurs in vivo. We initially characterized whole-body *ATF4*-depleted mice (WbATF4-KO), but breeding of these animals can be problematic ([@B41]), and we subsequently extended our analysis to mice with a liver-specific *ATF4* deletion (LsATF4-KO). Mice expressing Cre from the albumin promoter were bred to *ATF4* gene floxed mice in a manner similar to the liver-specific *PERK* knockout that our laboratories previously described ([@B57]). WbATF4-KO ([Figure 4](#F4){ref-type="fig"}) and LsATF4-KO ([Figure 5](#F5){ref-type="fig"}) mice and their wild-type (WT) controls were treated with 1 mg/kg tunicamycin or 0.3% dimethyl sulfoxide (DMSO) vehicle administered via an intraperitoneal (IP) injection for 6 h. As expected, *ATF4* mRNA and protein were induced upon tunicamycin treatment in WT livers, and ATF4 was minimally expressed in either knockout model ([Figures 4, A and E](#F4){ref-type="fig"}, and [5, A and E](#F5){ref-type="fig"}). Consistent with the loss of ATF4 transcriptional activity, there was significant reduction in the expression of ATF4-target genes *ASNS*, *FGF21*, and *CTH* in the WbATF4-KO and LsATF4-KO livers ([Figures 4, B and D](#F4){ref-type="fig"}, and [5, B and D](#F5){ref-type="fig"}).

![CHOP expressed independently of ATF4 in whole-body ATF4-knockout livers. WT and WbATF4-KO were injected IP with 1 mg/kg body weight Tm or vehicle indicating no treatment (NT) for 6 h. (A--D) Livers were collected, and mRNA levels were measured by qPCR for the indicated genes. (B) *ASNS* and *FGF21* represent ATF4-target genes. (C) *GADD34* and *ATF5* highlight genes regulated by both ATF4 and CHOP. (D) *CTH* and *SOD2* were analyzed to assess genes involved in mitochondrial function and oxidative stress. (E) The indicated proteins were measured by immunoblot analyses using lysates prepared from livers derived from mice treated with DMSO (--) or Tm (+) for 6 h. (F) Measurement of mRNAs from microarray data derived from livers of whole-body ATF6-knockout mice and their WT littermates ([@B71]). \**p* \< 0.05 indicates statistical significance among ER stress--treated livers, ^\#^*p* \< 0.05 indicates statistical significance among untreated liver tissues, and ^\$^*p* \< 0.05 indicates significance with respect to the untreated and treated tissues.](1536fig4){#F4}

![CHOP is expressed independently of ATF4 in liver-specific ATF4-knockout mice. WT and LsATF4-KO were injected IP with 1 mg/kg body weight Tm or vehicle indicating no treatment (NT) for 6 h. (A--D) Livers were collected, and mRNA levels for the indicated genes were measured by qPCR. (B) *ASNS* and *FGF21* are indicated ATF4-target genes. (C) *GADD34* and *ATF5* highlight genes regulated by both ATF4 and CHOP. (D) *CTH* and *SOD2* were analyzed to assess genes involved in mitochondrial function and oxidative stress. (E) Immunoblot analyses of the indicated proteins were carried out in livers obtained from mice treated with DMSO (−) or Tm (+) for 6 h. (F) Liver samples from WT and LsATF4-KO mice treated with TM for 24 h were compared for levels of MDA via fluorescence using the Lipid Peroxidation Kit from BioVision. (G) LsPERK-WT, LsPERK-KO, LsATF4-WT, and LsATF4-KO mice were treated with IP injection of 1 mg/kg tunicamycin or vehicle for 24 or 36 h, and caspase 3/7 activity was measured. Histological samples were also assessed for TUNEL-positive cells after 36 h of Tm treatment, and the presented results are the average counts of eight different histological sections. \**p* \< 0.05 indicates statistical significance among cells subjected to ER stress, ^\#^*p* \< 0.05 indicates significance among untreated cells, and ^\$^*p* \< 0.05 indicates significance with respect to the untreated vs. treated tissues.](1536fig5){#F5}

We next addressed the requirement for ATF4 for in vivo induction of key UPR gene markers. Activation of ATF6(N) protein in the liver during ER stress was largely independent of ATF4 function, and there was only modest reduction of induced *ATF6* mRNA in WbATF4-KO and LsATF4-KO compared with WT ([Figure 4, A and E](#F4){ref-type="fig"}, and [5, A and E](#F5){ref-type="fig"}). Of importance, there was only minimal reduction of induced *CHOP* mRNA upon ER stress in the *ATF4*-deleted livers and full induction of CHOP protein independent of ATF4 function. Expression at WT levels of ATF6 and CHOP can also be seen in the heterozygous mice for the ATF4-KO ([Figure 4E](#F4){ref-type="fig"}). Transcriptional expression of *GADD34* and *ATF5* depends on both CHOP and ATF4, and consistent with retention of CHOP function in the ATF4-knockout models, there was a partial induction of *GADD34* and *ATF5* mRNAs compared with WT ([Figures 4C](#F4){ref-type="fig"} and [5C](#F5){ref-type="fig"}). Taken together, these results are similar to our analyses with Hepa1-6 hepatoma cells and suggest that in the liver, *CHOP* and *ATF6* expression is uncoupled from ATF4 in the UPR. Of importance, reported microarray analyses of livers prepared from WT and *ATF6*α^−/−^ mice showed that loss of ATF6 significantly reduced *CHOP* mRNA expression basally and upon IP injection with tunicamycin ([@B71]; [Figure 4F](#F4){ref-type="fig"}), a finding consistent with our UPR analyses in Hepa1-6 cells ([Figure 2A](#F2){ref-type="fig"}).

As previously seen in the Hepa1-6 shATF4 cells, expression of *CTH* and *SOD2* mRNA was reduced in the absence of ATF4 ([Figures 4D](#F4){ref-type="fig"} and [5D](#F5){ref-type="fig"}). LsATF4-KO mice also displayed elevated levels of MDA independent of stress ([Figure 5F](#F5){ref-type="fig"}). Of importance, this resistance to oxidative stress in vivo can be conferred by basal expression of ATF4, and this protection can occur independent of PERK, as the LsPERK-KO did not show significant differences in MDA levels compared with WT.

LsPERK-KO livers were previously shown to trigger cell death during extended periods of ER stress ([@B57]). There was increased caspase 3/7 cleavage activity in LsPERK-KO mice upon treatment with 1 mg/kg tunicamycin for 24 or 36 h ([Figure 5G](#F5){ref-type="fig"}). By comparison, LsATF4-KO livers showed no change in the caspase activity compared with WT. Livers prepared from LsPERK-KO treated with tunicamycin also exhibited a robust increase in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)--positive cells, whereas LsATF4-KO showed a more moderate but still significant 10× increase compared with WT ([Figure 5G](#F5){ref-type="fig"}). These results indicate that PERK provides robust protection of livers exposed to ER stress, whereas ATF4 plays a more moderate role.

RNA sequencing analysis of LsATF4-KO mice
-----------------------------------------

To address the role of ATF4 in the genome-wide regulation of the UPR transcriptome, we carried out RNA sequencing (RNA-Seq) analysis using livers prepared from WT and LsATF4-KO mice treated with 1 mg/kg tunicamycin or vehicle for 6 h. The RNA-Seq featured single-end RNA sequencing with 100--base pair reads; ∼32 million reads were collected for each mouse, with three animals per group. Reads were mapped to the mouse mm9 genome using TopHat ([@B60], [@B61]), and expression levels were characterized using Cufflinks, Cuffmerge, and Cuffdiff ([@B62], [@B61]). Results were first analyzed by a volcano plot comparing the log~2~ of fold change to the −log~10~ of the *q* value ([Figure 6A](#F6){ref-type="fig"}). There were 4717 gene transcripts showing a significant change in WT liver upon ER stress (\>1.5-fold, *p* \< 0.05, false discovery rate \[FDR\] \< 0.05), with 2271 genes showing an increase and 2446 a decrease in expression. A total of 352 genes, or 7.5% of the total UPR changes, were significantly affected by loss of ATF4.

![ATF4 is required for expression of a subset of UPR genes. (A) RNA-Seq analyses measuring levels of gene transcripts from WT and LsATF4-KO mice treated with 1 mg/kg Tm or vehicle (NT) for 6 h. Volcano plot of WT NT vs. Tm, and WT Tm vs. LsATF4-KO Tm. (B) Levels of UPR gene transcripts by RNA-Seq analysis, which are organized into ATF4-dependent groups (*ASNS*, *FGF21*, *CTH*, *DDIT4*, and *CARS*) and genes bound by both ATF4 and CHOP (*CHOP*, *ATF5*, *GADD34*, *TRIB3*, *ATF6*).](1536fig6){#F6}

Key UPR target genes *ATF4*, *CHOP*, and *ASNS* were each significantly induced in the WT liver ([Figure 6A](#F6){ref-type="fig"}). Consistent with our quantitative PCR (qPCR) findings, the levels of *ASNS*, *FGF21*, and *CTH* were significantly lowered in the LsATF4-KO liver. By comparison, induced *CHOP* expression was not significantly affected by loss of ATF4 ([Figure 6B](#F6){ref-type="fig"}). The limited role of ATF4 in the UPR is noteworthy, given our earlier genome-wide analysis that nearly 50% of the gene transcripts showing significant changes in liver exposed to tunicamycin were dependent on PERK ([@B57]). We conclude that ATF4 is required for induction of only a portion of PERK-dependent genes. This finding suggests that there are other PERK-driven events that are critical for regulation of the UPR-directed gene expression.

It is noteworthy that many genes required ATF4 for full expression during basal conditions, suggesting that ATF4 plays a significant role in directing the transcriptome in seemingly nonstressed conditions in the liver. There were 385 genes that were altered by the loss of ATF4 during vehicle treatment. Pathway analysis of ATF4-targeted genes using PANTHER was performed on gene expression with a significant *q* value between WT and LsATF4-KO livers during either basal or ER stress conditions ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}; [@B43]; [@B42]). The analysis was performed by using the PANTHER statistical overrepresentation test, which involves comparing a user input list of genes against a reference list containing all genes. These lists were then subdivided on the basis of Gene Ontology (GO) classification, and then a binomial test was performed to determine overrepresentation of the user list of genes compared with the expected number if they occurred at random. Under basal conditions, several categories demonstrated greater-than-fivefold enrichment, including those representing fatty acid biosynthetic processes and fatty acid metabolic processes ([Table 1](#T1){ref-type="table"}). During ER stress, we identified three pathways with fold enrichment greater than five, including steroid biosynthetic process, cholesterol metabolic process, and sterol metabolic process ([Table 2](#T2){ref-type="table"}). Given that the top three pathways affected during ER stress--included genes involved in sterol and cholesterol metabolism, we next experimentally addressed the effect of *ATF4* loss on cholesterol.

###### 

Pathway analysis using PANTHER of altered genes in WT and LsATF4-KO livers in nonstressed conditions.

  GO category                                                    *Mus musculus* (reference)   Uploaded   Expected   Fold enrichment   ±    *p* value
  -------------------------------------------------------------- ---------------------------- ---------- ---------- ----------------- ---- -----------
  Regulation of liquid surface tension (GO: 0050828)             55                           9          0.95       \>5               \+   1.50E-04
  Cell--matrix adhesion (GO: 0007160)                            88                           12         1.52       \>5               \+   1.50E-05
  Fatty acid biosynthetic process (GO: 0006633)                  61                           8          1.05       \>5               \+   3.08E-03
  Locomotion (GO: 0040011)                                       63                           8          1.09       \>5               \+   3.87E-03
  Fatty acid metabolic process (GO: 0006631)                     252                          23         4.35       \>5               \+   4.12E-08
  Steroid metabolic process (GO: 0008202)                        198                          15         3.42       4.39              \+   5.98E-04
  Macrophage activation (GO: 0042116)                            173                          13         2.98       4.36              \+   2.99E-03
  Homeostatic process (GO: 0042592)                              208                          15         3.59       4.18              \+   1.07E-03
  Receptor-mediated endocytosis (GO: 0006898)                    217                          15         3.74       4.01              \+   1.76E-03
  Cell--cell adhesion (GO: 0016337)                              362                          22         6.24       3.52              \+   1.20E-04
  Cell adhesion (GO: 0007155)                                    550                          31         9.49       3.27              \+   3.06E-06
  Biological adhesion (GO: 0022610)                              577                          31         9.95       3.11              \+   8.88E-06
  Generation of precursor metabolites and energy (GO: 0006091)   290                          15         5          3                 \+   4.44E-02
  Lipid metabolic process (GO: 0006629)                          966                          47         16.66      2.82              \+   5.65E-08
  Endocytosis (GO: 0006897)                                      380                          18         6.55       2.75              \+   3.13E-02
  Immune system process (GO: 0002376)                            1480                         50         25.53      1.96              \+   1.13E-03
  Developmental process (GO: 0032502)                            2468                         75         42.57      1.76              \+   2.01E-04
  Localization (GO: 0051179)                                     2788                         76         48.09      1.58              \+   8.12E-03
  Cell communication (GO: 0007154)                               3175                         85         54.77      1.55              \+   4.81E-03
  Cellular process (GO: 0009987)                                 7033                         158        121.31     1.3               \+   1.12E-02

###### 

Pathway analysis using PANTHER of regulated genes in WT and LsATF4-KO livers during treatment with tunicamycin.

  GO category                                                          *Mus musculus* (reference)   Uploaded   Expected   Fold enrichment   ±    *p* value
  -------------------------------------------------------------------- ---------------------------- ---------- ---------- ----------------- ---- -----------
  Steroid biosynthetic process                                         90                           18         3.2        \>5               \+   6.08E-05
  Cholesterol metabolic process                                        92                           17         3.27       \>5               \+   4.79E-04
  Sterol metabolic process                                             99                           18         3.52       \>5               \+   2.52E-04
  Cellular hormone metabolic process                                   74                           13         2.63       4.94              \+   2.84E-02
  Renal system process                                                 77                           13         2.74       4.75              \+   4.32E-02
  Steroid metabolic process                                            194                          29         6.89       4.21              \+   1.67E-06
  Striated muscle cell development                                     115                          17         4.09       4.16              \+   1.01E-02
  Lipid homeostasis                                                    111                          16         3.94       4.06              \+   2.79E-02
  Renal system development                                             217                          31         7.71       4.02              \+   1.19E-06
  Organic hydroxy compound biosynthetic process                        142                          20         5.05       3.96              \+   2.56E-03
  Hormone metabolic process                                            121                          17         4.3        3.95              \+   1.97E-02
  Gland morphogenesis                                                  114                          16         4.05       3.95              \+   3.88E-02
  Positive regulation of lipid metabolic process                       122                          17         4.33       3.92              \+   2.19E-02
  Negative regulation of cellular response to growth factor stimulus   115                          16         4.09       3.92              \+   4.32E-02
  Kidney development                                                   197                          27         7          3.86              \+   4.22E-05
  Lipid transport                                                      206                          28         7.32       3.83              \+   2.64E-05
  Regulation of transmembrane transporter activity                     172                          23         6.11       3.76              \+   8.59E-04
  Organic acid biosynthetic process                                    217                          29         7.71       3.76              \+   2.02E-05
  Carboxylic acid biosynthetic process                                 217                          29         7.71       3.76              \+   2.02E-05
  Regulation of ion transmembrane transporter activity                 167                          22         5.93       3.71              \+   2.06E-03
  Monocarboxylic acid biosynthetic process                             146                          19         5.19       3.66              \+   1.56E-02
  Small-molecule biosynthetic process                                  316                          40         11.23      3.56              \+   1.01E-07
  Regulation of transporter activity                                   182                          23         6.47       3.56              \+   2.27E-03
  Lipid localization                                                   233                          29         8.28       3.5               \+   9.35E-05

Loss of ATF4 leads to alterations in the cholesterol pathways
-------------------------------------------------------------

Our RNA-Seq analysis suggested a role for ATF4 in metabolism of cholesterol and related bile acids ([Figure 7, A--D](#F7){ref-type="fig"}). ATF4 was required for expression of several key genes involved in bile acid synthesis, which represents one pathway for disposing of free cholesterol in hepatocytes. Among these synthetic genes, *CYP7A1*, encoding cholesterol 7α-hydoxylase, and *CYP27A1*, encoding sterol 27-hydoxylase, were significantly lowered in LsATF4-KO cells in both basal and ER stress conditions ([Figure 7, A and B](#F7){ref-type="fig"}). Expression of *HNF4α*, a gene that enhances transcription of *CYP7A1* ([@B14]; [@B31]), was also significantly reduced in LsATF4-KO livers. ATF4 is also required for full induction of *SOAT2*, which facilitates conversion of free cholesterol to esterified cholesterol ([Figure 7, A and C](#F7){ref-type="fig"}; [@B10]; [@B76]). Free cholesterol can be damaging to cells, and injury can be prevented by cholesterol esterification ([@B29]; [@B20]). *nCEH1* was significantly reduced in response to ER stress independent of ATF4. Expression of genes responsible for exporting free cholesterol was also altered in the LsATF4-KO mice. *ABCG5* and *ABCG8* encode transporters that function on the enterocyte side of the hepatocyte, which export free cholesterol ([Figure 7A](#F6){ref-type="fig"}; [@B37]). Expression of both genes was significantly lowered during ER stress, and loss of ATF4 further lowered the amounts of *ABCG5* and *ABCG8* mRNAs during both basal conditions ([Figure 7D](#F7){ref-type="fig"}). *ABCA1* encodes a transporter of free cholesterol from hepatocytes to the plasma, and consistent with a previous report ([@B48]), *ABCA1* mRNA was reduced during ER stress. Deletion of *ATF4* further reduced *ABCA1* expression independent of stress ([Figure 7D](#F7){ref-type="fig"}). Together these findings suggest that ATF4 contributes to expression of key genes involved in cholesterol metabolism and transport.

![Loss of ATF4 leads to increase in free cholesterol within the liver. (A) ATF4-targeted gene functions in hepatocyte cholesterol metabolism. (B--F) WT and LsATF4-KO mice were injected IP with 1 mg/kg Tm or vehicle (NT) for 6 h. Levels of the indicated mRNAs were measured by qPCR (B--D) or cholesterol content analysis (E, F). (B--D) Genes involved in bile acid synthesis (*CYP7A1*, *CYP27A1*, *HNF4α*), cholesterol esterification (*SOAT2*), or cholesterol export (*ABCA1*, *ABCG5*, *ABCG8*) were significantly reduced due to ATF4 loss. (E, F) WT and LsATF4-KO livers treated with Tm or vehicle (NT) were analyzed for total cholesterol content in the serum (E) and within tissue (F). \**p* \< 0.05 indicates statistical significance with respect to the ER-treated tissues, ^\#^*p* \< 0.05 indicates significance among untreated tissues, and ^\$^*p* \< 0.05 indicates significance between respective untreated ER stress tissues.](1536fig7){#F7}

We next determined whether there are changes in free cholesterol levels upon loss of ATF4 and ER stress. There were lowered levels of serum cholesterol in the LsATF4-KO mice compared with WT ([Figure 7E](#F7){ref-type="fig"}), a finding consistent with that reported for WbATF4-KO ([@B72]). Furthermore, cholesterol was lowered in both WT and LsATF4-KO mice upon treatment with tunicamycin ([Figure 7E](#F7){ref-type="fig"}). Although there was a trend for the LsATF4-KO mice to exhibit lower total cholesterol during ER stress than with WT, it did not reach statistical significance. We also measured the levels of free and total cholesterol in liver tissue ([Figure 7F](#F7){ref-type="fig"}). Liver tissue from LsATF4-KO mice during stress showed significantly increased levels of free cholesterol, based on assays in the absence of esterase that represents free cholesterol. Integration of ATF4-directed gene expression in cholesterol metabolism will be considered further in the *Discussion*.

DISCUSSION
==========

In this study, we used biochemical and RNA-Seq analysis to determine that ATF4 is required for only 7.5% of genes regulated by ER stress, compared with nearly 50% in an LsPERK-KO model ([@B57]). This subset includes genes involved in amino acid metabolism, resistance to oxidative stress, and cholesterol metabolism. Deletion of *ATF4* alters genes that are required for the conversion of cholesterol to bile acid (*CYP7A1*), esterification of cholesterol (*SOAT2*), and transport from the hepatocyte (*ABCA1*), and when *ATF4* loss is coupled with ER stress, it results in an increase in free cholesterol within hepatocytes ([Figure 7](#F7){ref-type="fig"}; [@B21]; [@B48]). Of importance, ATF4 has a role in gene expression during basal conditions, with 385 genes altered by the loss of *ATF4* in the absence of apparent stress ([Table 1](#T1){ref-type="table"}). The consequences of *ATF4* in basal gene expression are illustrated by the finding that deletion of *ATF4* in the liver is required for prevention of oxidative stress ([Figure 5F](#F5){ref-type="fig"}), a finding consistent with a report on cultured MEF cells ([@B25]). In cultured Hepa1-6 cells, we also found a linkage between basal *ATF4* expression and mitochondrial membrane potential ([Figure 1F](#F1){ref-type="fig"}). Finally, loss of ATF4 in cultured Hepa1-6 cells subjected to ER stress led to an increase in cell death, and there was also significant cell death in the livers of LsATF4-KO mice as measured by TUNEL, although the amount of cell death was much less than in *PERK* deficiency ([Figures 2D](#F2){ref-type="fig"} and [5G](#F5){ref-type="fig"}).

ATF6 is a primary inducer of *CHOP* expression in the liver during ER stress
----------------------------------------------------------------------------

Although certain characteristics were shared between cultured MEF and Hepa1-6 cells and liver in vivo, there were also striking differences. In contrast to MEF cells, ATF4 was not required for induced *CHOP* mRNA and protein in liver exposed to ER stress ([Figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). This ATF4-independent expression of *CHOP* was also seen in the Hepa1-6 cell line ([Figure 1](#F1){ref-type="fig"}), for which ATF6 was a necessary transcription factor for *CHOP* expression during ER stress ([Figure 2](#F2){ref-type="fig"}). Induction of *CHOP* expression depended on both ATF4 and ATF6 during halofuginone treatment, which inhibits tRNA charging in the cytosol. It is noteworthy that there is a more modest activation of ATF6 during halofuginone exposure than with tunicamycin, although ATF6 still plays a role in the expression of *CHOP*.

ATF6 was previously shown to be a component of *CHOP* expression through an endoplasmic reticulum stress response element situated in its promoter ([@B38]). The role of ATF6 has been overshadowed by the requirement in MEF culture cells on ATF4 binding for the amino acid response element within the *CHOP* promoter ([@B6]; [@B38]) and the idea that the three arms of the UPR operate independently. This switch from ATF4- to ATF6-dependent *CHOP* expression may result in part from the timing of activation of ATF4 protein versus ATF6 or the availability of their binding partners. ATF6 is rapidly cleaved and activated upon ER stress, whereas ATF4 requires preferential translation, and its induction occurs later in the UPR. These findings support the idea that PERK/ATF6 cross-talk is a primary driver of *CHOP* expression within the liver ([Figure 3E](#F3){ref-type="fig"}).

ATF4 is responsible for a small subset of PERK-dependent genes during ER stress
-------------------------------------------------------------------------------

RNA-Seq analysis suggests an expanded role for ATF4-directed gene expression in the liver not subjected to any apparent stress. A total of 385 genes were significantly altered by the loss of *ATF4* basally, which exceeded those regulated during ER stress. The ATF4-target genes expressed during basal conditions are represented by metabolic processes of fatty acids and steroids and cell adhesion ([Table 1](#T1){ref-type="table"}). ATF4 was previously shown to promote metastasis in a tumor environment, but it is also required basally ([@B17]). Deletion of *ATF4* significantly changed the expression of 352 genes among the 4717 genes altered during ER stress. The unexpected small subset of genes requiring ATF4 in the UPR compared with those involving PERK emphasizes that PERK can facilitate multiple transcriptional control networks, including those for *ATF6* and *XBP1* ([@B57]). In addition, ATF4 and CHOP ChIP-Seq analyses indicated that induced CHOP can play a direct role in the expression of genes that are also targeted by ATF4 ([@B23]). Thus the PERK/ATF6/CHOP arm can alleviate loss of *ATF4* for transcriptional regulation during ER stress by robustly activating CHOP.

Deletion of *ATF4* in the liver demonstrates its role in prevention of oxidative stress independent of stress ([Figure 5F](#F5){ref-type="fig"}). There was a lack of a difference in MDA levels in cultured Hepa1-6 cells depleted of ATF4 ([Figure 1E](#F1){ref-type="fig"}). Loss of ATF4 in the Hepa1-6 cells did lead to a striking reduction in mitochondrial membrane potential ([Figure 1F](#F1){ref-type="fig"}), and reduced ROS production via oxidative phosphorylation might help to explain the absence of observed oxidative stress in Hepa1-6 cells depleted of *ATF4*. Rapidly proliferating cells cultured in media with high glucose concentration can proceed by aerobic glycolysis ([@B63]); however, we did not observe changes in oxidative stress in the ATF4-depleted Hepa1-6 cells even when cultured in medium with lower amounts of glucose (unpublished data). It was reported that ATF4 contributes to increased H~2~S sulfhydration of certain metabolic proteins during ER stress, altering their activity ([@B22]). The H~2~S sulfhydration occurs on several proteins within glycolysis and the tricarboxylic acid cycle, leading to an increase in glycolysis and a decrease in oxidative phosphorylation, which can be restored through *CTH* inhibition ([@B22]). This connection between ATF4 and energy metabolism, together with the reduced mitochondrial membrane potential seen in the Hepa1-6 cells, warrants further investigation.

ATF4 is involved in cholesterol metabolism
------------------------------------------

Our biochemical and RNA-Seq analysis established the importance of ATF4 in the expression of genes important in cholesterol metabolism and transport ([Figure 7, B--D](#F7){ref-type="fig"}). Loss of *ATF4* led to decreased expression of *SOAT2*, a gene that was also identified as an ATF4 and CHOP target by ChIP-Seq analyses ([@B23]), suggesting a lowered conversion of free cholesterol to cholesterol esters in the livers of LsATF4-KO mice ([Figure 7, A and C](#F7){ref-type="fig"}). Free cholesterol would also be converted to bile acids at a reduced rate in the *ATF4*-deleted livers due to reduced expression of genes encoding CYP7A1 and CYP27A1 ([Figure 7B](#F7){ref-type="fig"}). Export of free cholesterol would also be expected to be adversely affected in LsATF4-KO mice ([Figure 7A](#F7){ref-type="fig"}). Previous studies suggested that ER stress results in ∼50% reduction in *ABCA1* mRNA levels and decreased plasma cholesterol concentration ([@B48]). We determined that deletion of *ATF4* results in a similar 50% reduction in *ABCA1* mRNA basally, which is further reduced under stress ([Figure 7D](#F7){ref-type="fig"}). We also showed that ER stress triggered decreased serum cholesterol, which is further lowered both basally and during stress upon loss of *ATF4* ([Figure 7E](#F7){ref-type="fig"}). Changes in gene expression and cholesterol levels may be a direct consequence of ATF4 transcriptional regulation or indirect through downstream UPR effectors. Collectively, these ATF4-directed changes in expression of genes involved in cholesterol metabolism and transport help to explain the increased free cholesterol load within liver tissues of the LsATF4-KO mice ([Figure 7F](#F7){ref-type="fig"}).

MATERIALS AND METHODS
=====================

Animals
-------

Animal protocols were approved by the Institutional Animal Care and Use Committees at Rutgers University and the Indiana University School of Medicine. WbATF4-KO mice were as described ([@B41]) and obtained from Jackson Laboratory (Bar Harbor, ME). C57BL/6J mice homozygous for the *LoxP* allele of *ATF4* (ATF4^fl/fl^; [@B19]) were bred with C57BL/6J mice heterozygous for the Cre recombinase gene under an albumin gene promoter (*AlbCre*) to create a liver-specific knockout of *ATF4*, LsATF4-KO (*AlbCre^−^\** ATF4^fl/fl^). Cre-negative mice from these litters expressed WT levels of *ATF4* and were used as controls. Genotyping showed efficient *ATF4* gene deletion, and proteins level reductions were seen in response to tunicamycin treatment ([Figure 5, A and E](#F5){ref-type="fig"}). Female adult mice (five to eight per treatment group) aged 3--6 mo were individually housed in plastic cages with soft bedding, maintained on 12-h light/dark cycles, and freely provided tap water and commercial pelleted diet (5001 Laboratory Rodent Diet; LabDiet, St. Louis, MO). Mice received IP injections of tunicamycin at a dose of 1 mg/kg body weight, whereas control mice were given a vehicle consisting of a solution of 0.3% DMSO in phosphate-buffered saline (PBS). Mice were killed by decapitation using a rodent guillotine at 6, 24, and 36 h after treatment, as indicated. Livers were rinsed with ice-cold PBS and then snap frozen in liquid nitrogen or fixed in 4% paraformaldehyde. Mice homozygous for the *LoxP* allele of *PERK* (PERK^/fl^) were previously described ([@B57]) and bred with transgenic mice heterozygous for *AlbCre* to create a liver-specific knockout of *PERK*, LsPERK-KO (*AlbCre^−^\** PERK^/fl^). Cre-negative mice from these litters expressed WT levels of *PERK* and were used as controls.

Cell culture and lentivirus shRNA knockdown
-------------------------------------------

WT and *ATF4*^−*/*−^ MEF cells ([@B25]) and mouse hepatoma Hepa1-6 cells were cultured in DMEM (4.5 g/l glucose) supplemented with 1× nonessential amino acids (SH3023.01; HyClone), 1× MEM essential amino acids (SH30598.01; HyClone), and 50 μM β-mercaptoethanol, as described previously ([@B25]). shRNA-directed knockdowns of *ATF4*, *ATF5*, *ATF6*, and *CHOP*, were performed using a lentivirus delivery system featuring Addgene third-generation plasmids and mission shRNA clones (Sigma-Aldrich, St. Louis, MO) for generation of the viral particles. The shRNAs used in this study were as follows: *ATF4*, TRCN0000071726, TRCN0000071727; *ATF5*, TRCN0000075556, TRCN0000075553; *ATF6*, TRCN0000321326, TRCN0000321328; *CHOP*, TRCN0000103709, TRCN0000305677; and control Ctrl, TRC2-puro SHC201V. Cultured cells were treated with 2 μM tunicamycin, 1 μM MG132, or 50 nM halofuginone for the indicated times. Cultured cells that were treated with halofuginone were first washed with PBS to remove DMEM before addition of medium containing dialyzed fetal bovine serum (FBS) and subsequent addition of halofuginone.

Immunoblot analyses
-------------------

Cellular lysates were prepared from cultured MEF and Hepa1-6 cells using RIPA-buffered solution containing 50 mM Tris-HCl (pH 7.5), 150 mM sodium chloride, 1% Nonidet P-40, 0.1% SDS, 100 mM sodium fluoride, 17.5 mM β-glycerophosphate, 0.5% sodium deoxycholate, and 10% glycerol that was supplemented with EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland). Liver samples were prepared as previously described ([@B8]). Proteins in the cell lysates were separated by SDS--PAGE, followed by immunoblot analysis using chemiluminescence as previously described ([@B57]). Primary and secondary antibodies used in immunoblot analyses include those from Abcam (Cambridge, United Kingdom) recognizing eIF2α-P (ab32157) and from Cell Signaling Technology (Danvers, MA) for actin (\#8457). Antibodies for GADD34 (sc-8327) and CHOP (sc-7351) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The eIF2α total antibody was a kind gift from the laboratory of Scot Kimball (Pennsylvania State College of Medicine, Hershey, PA). ATF6 antibody was prepared in rabbits using the mouse ATF6 N-terminal amino acids 6--207 as the antigen and used at a concentration of 1:250 in 5% milk powder in PBS with 0.2% Tween 20, as previously described ([@B57]). ATF4 and ATF5 antibodies were prepared against the corresponding recombinant human proteins, which were affinity purified. Secondary antibodies were purchased from Bio-Rad (Hercules, CA). The Odyssey infrared imaging system (LI-COR, Lincoln, NE) was used for actin, eIF2α total, and CHOP antibodies. Protein levels were measured by densitometry using the ImageJ ([@B50]).

Reverse transcription and real-time PCR
---------------------------------------

Total RNA was extracted from cultured Hepa1-6 and MEF cells and from liver tissues by using TRIzol reagent (Life Technologies, Grand Island, NY) following the manufacturer's instructions. Reverse transcription was performed with 1 μg of each RNA sample using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Levels of the indicted mRNAs were determined by qPCR. Primers used for SYBR Green are listed in Supplemental Table S1. Amplification and detection were measured on the Realplex^2^ Master Cycler (Eppendorf, Hauppauge, NY). All experiments were performed with biological and technical triplicates. Results were generated using the comparative *Ct* method and are expressed as fold change relative to the untreated control.

Histology
---------

Tissues were fixed in 4% paraformaldehyde, frozen, and then sectioned at 10 μM using a cryostat. TUNEL assays were performed according to the manufacturer's instructions (Trevigen TACS 2 TdT-Blue Label In Situ Apoptosis Detection Kit; R&D Systems, Minneapolis, MN). TUNEL-positive cells were measured from equal-size sections of livers derived from similar location within the tissues. Digital images of the selected areas were prepared at 200× and imported into Scion Image for Windows (Scion, Frederick, MD), and TUNEL-positive cells were manually marked and counted.

RNA-Seq analysis
----------------

WT and LsATF4-KO mice were injected IP with 1 mg/kg tunicamycin for 6 h, or vehicle and total RNA was prepared with TRIzol reagent (Life Technologies) following the manufacturer's instructions. RNA sequencing was performed using an Illumina HiSeq2000 at the Sulzberger Genome Center, Columbia University (New York, NY), with single-end reads and a read length of 100 base pairs. Real-time analysis was used for base calling. Fastq files were mapped to the mouse genome (NCBI37/mm9) using TopHat (version 2.0.4). Mapped reads were then assembled via Cufflinks (version 2.0.2) with the default settings. Assembled transcripts were then merged using the Cuffmerge program with the reference genome. Analysis of mRNA levels was carried out using the Cuffdiff program, with samples being grouped by treatment condition, giving four conditions and three replicates per group. Samples were considered if they demonstrated a fold change between WT no stress treatment (NT) and WT tunicamycin (TM) of ≥1.5 and if their *q* value, an FDR-adjusted *p* value with FDR set at 0.05, was ≤0.05. Venn diagrams were created with the use of the Venn diagram program (Venny 2.0.2) available at bioinfogp.cnb.csic.es/tools/venny/. Volcano plots comparing log~10~(statistical relevance) to log~2~(fold change) were generated using R (version 3.1.1), using the base plotting system and calibrate library. RNA-Seq data are deposited at the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)) under the series number GSE76771.

Luciferase assays
-----------------

Luciferase assays were carried out in six-well plates with the Dual Luciferase Reporter Assay System according to the manufacturer's instructions (Promega, Madison, WI). The plasmid p5XATF6GLC3 used for measuring ATF6 activity plasmid was provided by Ron Prywes (Columbia University) and was previously described ([@B67]). This reporter contains five ATF6-binding elements fused to the firefly luciferase reporter gene and was cotransfected into Hepa1-6 cells along with a *Renilla*-expressing plasmid for normalization. Measurements were determined as the relative light units (RLUs) of the firefly luciferase to the *Renilla* luciferase.

Cholesterol analysis
--------------------

Cholesterol content was measured in lysates prepared from liver tissues by using the Amplex Red Cholesterol Assay Kit (Molecular Probes, Eugene, OR). Cholesterol standards, liver lysate samples, and resorufin positive control were placed onto a 96-well plate in a volume of 50 μl (100 μl for the resorufin) per well before the addition of the working solution of 300 μM Amplex Red reagent. Plates were then incubated for 30 min at 37°C and protected from light sources. Resorufin, the product of the Amplex Red reagent, was then measured in a Synergy H1 (BioTek, Winooski, VT) fluorescence microplate reader using excitation of 530 nm and emission detection of 590 nm. Fluorescence intensity was then used to calculate micrograms of cholesterol-based values from the standard curve, which were normalized for protein concentrations determined for lysates.

Cell survival assays
--------------------

The Calcein AM Viability Dye (eBioscience, San Diego, CA) was used to measure cell survival. This assay was performed in 96-well plates and evaluated according to manufacturer's instructions using a Synergy H1 reader with excitation wavelength of 495 nm and emission detection at 515 nm. We cultured 5 × 10^3^ cells in DMEM supplement with 10% FBS, penicillin (100 IU/ml), and streptomycin (100 μg/ml) in a final concentration of 2 μM tunicamycin, 1 μM MG132, or no stress agent for 24 h. Calcein-AM dye was then added for 30 min at room temperature before measurement of fluorescence. The caspase 3/7 assay was performed using the Caspase-Glo 3/7 Kit (Promega). This assay was performed in 96-well plates and done as previously described ([@B36]). Livers were homogenized in a hypotonic extraction buffer (25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5, 5 mM MgCl~2~, 1 mM ethylene glycol tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, and 1 μg/ml aprotinin, leupeptin, and pepstatin). The livers were then centrifuged at 13,000 rpm for 30 min at 4°C. Equal volumes of diluted extract (10 μg/ml) and Caspase-Glo reagent were plated in the 96-well plates before 1-h incubation at room temperature. The results were read using a Synergy H1 plate reader.

MDA analysis
------------

The Lipid Peroxidation (MDA) Colorimetric/Fluorometric Assay kit from BioVision (Milpitas, CA) was used to measure the natural byproduct of lipid peroxidation, MDA. Liver tissue was obtained from LsPERK-WT, LsPERK-KO, LsATF4-WT, and LsATF4-KO mice that were treated with 0.3% DMSO or 1 mg/kg tunicamycin for 24 h before livers were collected. A 10-mg amount of liver tissue was prepared in MDA lysis buffer and then sonicated before centrifugation. Cells were collected with the MDA lysis buffer and sonicated. Cell lysate protein was calculated via Lowery assay to allow normalization of samples per milligram of protein used. The MDA-TBA adduct was colorimetrically detected at 532 nm, and MDA concentration was adjusted according to the mass of liver tissue used for each sample and the standard curve. Samples were measured on a Synergy H1 fluorescence microplate reader.

MitoTracker analysis
--------------------

We plated 15,000 Hepa1-6 shCtrl and Hepa1-6 shATF4 cells per well in a 96-well plate. Cells were treated with vehicle or 2 μM rotenone for 6 h. The medium was removed, and 100 μl of MitoTracker Red (ThermoFisher, Waltham, MA) was added in serum-free DMEM plus 10 μg/ml Hoechst stain (ThermoFisher). The cells were incubated at 37°C for 1 h before removing the probes and washing twice with DMEM. The cells were then imaged using spinning disk confocal microscopy using Opera (PerkinElmer, Waltham, MA) and quantified using the program Columbus as previously described ([@B68]).

Statistics
----------

All data are shown as mean ± SD and from at least three independent experiments. Statistical significance was determined using the two-tailed Student's *t* test. Multiple testing between groups was assessed using a one-way analysis of variance followed by a post hoc Tukey honest significant difference test to compare multiple groups. \**p* \< 0.05 indicates statistical significance with respect to the treated samples between the two cell types; ^\#^*p* \< 0.05 indicates statistical significance with respect to the untreated samples between the two cell types; and ^\$^*p* \< 0.05 indicates statistical significance between untreated sample versus ER stress for each cell type.
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